3.14
Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Evoke Pharma (EVOK) to Present Key Metoclopramide Study at DDW 2025 | EVOK Stock News - GuruFocus
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia In - GuruFocus
Evoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025 - Nasdaq
Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba - The Manila Times
Evoke Pharma to Present New Data Comparing Tardive - GlobeNewswire
Groundbreaking Safety Analysis: How 100M+ Patient Study Could Reshape Metoclopramide Treatment Guidelines - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Functional Dyspepsia Drug Industry Report 2025-2034: Market Dynamics, Trends, and Forecasts - WhaTech
Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update - Defense World
FY2025 Earnings Estimate for TSE:MNO Issued By Cormark - Defense World
Top Market Trend Impacting Digestive and Intestinal Remedies Development in the Coming Years:Technological ... - WhaTech
Evoke Pharma stock hits 52-week low at $2.01 amid downturn By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.01 amid downturn - Investing.com India
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Call Transcript - MSN
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
US Reciprocal Tariffs Evoke Mixed Response From India Inc - Free Press Journal
Is The Market Punishing Lynch Group Holdings Limited (ASX:LGL) For Its Mixed Fundamentals? - AInvest
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
Evoke Pharma stock hits 52-week low at $2.43 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.43 amid challenges - Investing.com India
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7% - Defense World
Tenaz Energy Corp. (OTCMKTS:ATUUF) Short Interest Update - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Evoke Pharma (NASDAQ:EVOK) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com - Defense World
Bleichroeder LP Significantly Reduces Stake in Evoke Pharma Inc - GuruFocus
Bleichroeder LP's Strategic Acquisition of Evoke Pharma Inc Shar - GuruFocus.com
Evoke Pharma stock hits 52-week low at $3.4 amid challenges - Investing.com Australia
Evoke Pharma stock hits 52-week low at $3.4 amid challenges By Investing.com - Investing.com South Africa
Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower - Simply Wall St
Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan
Earnings call transcript: Evoke Pharma Q4 2024 reports strong sales growth - Investing.com Australia
Evoke Pharma’s Earnings Call Highlights Revenue Growth and Strategic Partnerships - TipRanks
Evoke Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evoke Pharma Inc (EVOK) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):